Brief: Jazz Pharmaceuticals Provides Update On Zepzelca Phase 3 Trial
12/06/2026 13:07
BRIEF-Jazz Pharmaceuticals Provides Update On Zepzelca Phase 3 Trial June 12 (Reuters) - Jazz Pharmaceuticals PLC JAZZ.O:
JAZZ PHARMACEUTICALS PROVIDES UPDATE ON ZEPZELCA® (LURBINECTEDIN) PHASE 3 LAGOON TRIAL IN SECOND-LINE SMALL CELL LUNG CANCER
JAZZ PHARMACEUTICALS - PHASE 3 LAGOON TRIAL OF ZEPZELCA IN SECOND-LINE SCLC DOES NOT MEET PRIMARY ENDPOINT
JAZZ PHARMACEUTICALS - NO NEW SAFETY SIGNALS IDENTIFIED FOR ZEPZELCA IN LAGOON TRIAL
JAZZ PHARMACEUTICALS - LAGOON TRIAL RESULTS DO NOT IMPACT 2026 GUIDANCE
Source text: ID:nPn8WSdP3a
Further company coverage: JAZZ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jazz Pharmaceuticals
See all newsBrief: Jazz Pharmaceuticals Enters Amendment No. 4 To Credit Agreement On Sept 23, 2026
U.S. STOCKS ON THE MOVE-BWX Technologies, Synopsys,Burlington Stores
U.S. STOCKS ON THE MOVE-Jazz Pharmaceuticals, Celularity, Infleqtion
Jazz Pharma dips after upsized $1.1 bln convertible offering
Brief: Jazz Pharmaceuticals Announces Private Offering Of $1.0 Billion Of Exchangeable Senior Notes Due 2032